ABBV · 10-Q · 2026Q2 · Full report
Regulatory Environment
AbbVie Inc. · 2026-08-03 · Importance 34 · Surprise 60 · In source text
In January 2026, AbbVie entered a voluntary agreement with the U.S. government to lower Medicaid prices and expand affordable direct-to-patient offerings. AbbVie also pledged $100 billion of U.S.-based research and development and capital investments, including manufacturing, over the next decade. In exchange, the U.S. government agreed to provide a three-year exemption from tariffs and future price mandates. Separately, the Inflation Reduction Act requires government-set Medicare prices for Botox in Parts B and D beginning in 2028.
Key facts
- Centers for Medicare and Medicaid Services selected Botox as one of 15 medicines subject to government-set prices in Medicare Parts B and D beginning in 2028. source
- Under the January 2026 voluntary agreement, the U.S. government agreed to provide AbbVie a three-year exemption from tariffs and future price mandates. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | negative | probable | — | Centers for Medicare and Medicaid Services selected Botox as one of 15 medicines subject to government-set prices in Medicare Parts B and… |
| operating_income | positive | committed | — | Under the January 2026 voluntary agreement, the U.S. government agreed to provide AbbVie a three-year exemption from tariffs and future… |